Pharmaceuticals & Therapeutics

The Chinese pharma giant's Q1 results reveal a successful pivot to innovation, with blockbuster deals and a strategic Nasdaq listing paving its global path.

A record-breaking medical conference reveals a major shift in medicine, as practitioners move from simply managing aging to pursuing biological age reversal.

Adocia extends its cash runway to 2027 with a new loan, but the deal could make its key investor the largest shareholder, creating a dilution dilemma.

New long-term data for FLT201 gene therapy could signal a paradigm shift from lifelong treatments for patients with Gaucher disease type 1.

As COVID revenues fall, BioNTech bets its future on a robust oncology pipeline. The upcoming Q1 2026 report will reveal the financial health of this pivot.

Hyalex Orthopaedics’ new FDA-cleared Slalom™ implant, using cartilage-mimicking tech, offers a motion-preserving alternative to joint fusion.

A novel staple-like device from Inovedis gains expanded FDA approval, promising faster, less invasive repairs for a vast range of orthopedic injuries.

Pop icon Keung To's real-life pain story is the heart of a new campaign for a 27-year-old TCM brand, blending tradition with star power and fan frenzy.

ProRx Pharma touts a major expansion to meet drug demand, but recent FDA warnings and massive recalls raise serious questions about its quality and safety.

A new partnership aims to develop a diagnostic test for a hidden cancer biomarker, potentially unlocking a targeted therapy for patients with grim prognoses.

A UK biotech's Rincell-1 therapy enters human trials, aiming to regenerate auditory nerves and restore hearing where current technology falls short.

With a fresh $60 million IPO, JATT II is targeting the next wave of healthcare innovators using AI and machine learning to revolutionize drug discovery.

With a $719M war chest from its blockbuster IPO, Kailera Therapeutics is poised to challenge the dominance of Lilly and Novo in the lucrative obesity market.

A novel 'payload-bearing' drug shows potent preclinical activity against a rare pediatric cancer, paving an accelerated path to human trials.

Millions suffer from osteoporosis, but many refuse injections. Now, a biotech company's oral pill aims to bridge a massive treatment gap. Here's how.

Tenvie Therapeutics begins human trials for TNV108, a drug that targets the root cause of nerve decay, offering a potential disease-modifying breakthrough.

Upcoming Phase 1 data for ABCL635 could validate a novel antibody approach for hot flashes, challenging the market and offering new hope for millions.

TruHeight Vitamins lands in Target stores nationwide, but a federal settlement over its growth claims casts a shadow on the major retail expansion.

Biogen consolidates worldwide rights for its promising immunology drug felzartamab, acquiring China rights from TJ Biopharma in a strategic $850M deal.

Blue Cross Blue Shield of Michigan postpones a major payment change after intense, coordinated pressure from osteopathic physician groups.